✦ LIBER ✦

A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer

✍ Scribed by Judith K Wolf; Diane C Bodurka; Jacalyn B Gano; Michael Deavers; Lois Ramondetta; Pedro T Ramirez; Charles Levenback; David M Gershenson

Book ID: 113959374
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 118 KB
Volume: 94
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2004.05.041

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Weekly docetaxel for patients with plati

Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study

✍ Fumitoshi Terauchi; Takayuki Hirano; Hideki Taoka; Kazuo Masaki; Yasuhiro Yamamo 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 179 KB

A Phase I Study of Paclitaxel, Doxorubic

A Phase I Study of Paclitaxel, Doxorubicin, and Cisplatin in Patients with Previously Untreated Epithelial Ovarian Cancer

✍ R.Wendel Naumann; Ronald D. Alvarez; George A. Omura; Ellen Segars; Larry C. Kil 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Phase 2 Study of TLK286 (GST P1-1 Activa

Phase 2 Study of TLK286 (GST P1-1 Activated Glutathione Analog) in patients with platinum and paclitaxel refractory/resistant advanced epithelial ovarian cancer

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 265 KB

Phase 2 study of canfosfamide in combina

Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer

✍ John J Kavanagh; Charles F Levenback; Pedro T Ramirez; Judith L Wolf; Carla L Mo 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 404 KB

A phase 1 and pharmacodynamic study of d

A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer

✍ Fang Fang; Curt Balch; Jeanne Schilder; Timothy Breen; Shu Zhang; Changyu Shen; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 412 KB 👁 2 views

## Abstract ## BACKGROUND: Aberrant DNA methylation is a hallmark of cancer, and DNA methyltransferase inhibitors have demonstrated clinical efficacy in hematologic malignancies. On the basis of preclinical studies indicating that hypomethylating agents can reverse platinum resistance in ovarian c

A pilot study of three-cycle consolidati

A pilot study of three-cycle consolidation chemotherapy with paclitaxel and platinum in epithelial ovarian cancer patients with clinical complete response after paclitaxel and platinum chemotherapy

✍ S.-J. LEE; J.-W. LEE; J.A. MIN; C.-S. PARK; B.-G. KIM; J.-H. LEE; D.-S. BAE 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB